- Home
- REXR vs LEGN Comparison
REXR vs LEGN Comparison
Compare REXR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REXR
- LEGN
- Stock Information
- Founded
- REXR 2013
- LEGN 2014
- Country
- REXR United States
- LEGN United States
- Employees
- REXR N/A
- LEGN N/A
- Industry
- REXR Real Estate Investment Trusts
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- REXR Real Estate
- LEGN Health Care
- Exchange
- REXR Nasdaq
- LEGN Nasdaq
- Market Cap
- REXR 9.3B
- LEGN 6.3B
- IPO Year
- REXR 2013
- LEGN 2020
- Fundamental
- Price
- REXR $40.55
- LEGN $33.13
- Analyst Decision
- REXR Hold
- LEGN Buy
- Analyst Count
- REXR 10
- LEGN 11
- Target Price
- REXR $41.70
- LEGN $71.90
- AVG Volume (30 Days)
- REXR 2.3M
- LEGN 1.2M
- Earning Date
- REXR 10-15-2025
- LEGN 11-11-2025
- Dividend Yield
- REXR 4.24%
- LEGN N/A
- EPS Growth
- REXR 11.21
- LEGN N/A
- EPS
- REXR 1.35
- LEGN N/A
- Revenue
- REXR $986,532,000.00
- LEGN $796,838,000.00
- Revenue This Year
- REXR $8.29
- LEGN $70.27
- Revenue Next Year
- REXR $4.54
- LEGN $50.28
- P/E Ratio
- REXR $30.12
- LEGN N/A
- Revenue Growth
- REXR 13.72
- LEGN 74.75
- 52 Week Low
- REXR $29.68
- LEGN $27.34
- 52 Week High
- REXR $49.61
- LEGN $51.77
- Technical
- Relative Strength Index (RSI)
- REXR 46.54
- LEGN 48.04
- Support Level
- REXR $39.41
- LEGN $31.18
- Resistance Level
- REXR $42.10
- LEGN $33.21
- Average True Range (ATR)
- REXR 0.77
- LEGN 1.19
- MACD
- REXR -0.31
- LEGN 0.12
- Stochastic Oscillator
- REXR 38.06
- LEGN 83.36
About REXR Rexford Industrial Realty Inc.
Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.